Evolving, Pivoting, Growing: Our Journey to Becoming the Preferred CRO in the Industry

Cliantha Research, full-service clinical research organization (CRO), provides comprehensive and integrated offerings in Early Phase (BA/BE and Phase I) trials, Late Phase (Phase II-IV) patient-based trials, Consumer Clinical Research, Bioanalytical, IVRT/IVPT , Biometrics, Medical Services, Allergy Testing - Environmental Exposure Chambers (EECs) and Veterinary Therapeutics (Preclinical Bioanalytical).

Cliantha, by leveraging on the depth of experience provides ethical, value-added customer centric services rooted in excellence, thereby enabling clinical development of pharmaceutical, biotech & healthcare companies. With strategic acquisitions globally, Cliantha has widened the horizon of clinical research & support services for end-to-end developmental needs across.

With over 21 years of excellence in clinical research, we continue to advance studies across diverse therapeutic areas—leveraging innovation to drive efficiency throughout every phase of the clinical development process.

With several advanced clinical sites and bio-analytical laboratories in India and North America, Cliantha now has presence in 3 countries along with a strong team of 1500+ professionals. Some of the key regulators, such as the USFDA, GCC, EMA, AGES, ANVISA, MCC South Africa, and others have successfully inspected Cliantha across the globe.

Unified under Cliantha, Delivering Excellence Across Services

In 2011, Cliantha acquired HillTop Research, a CRO founded in 1947 and recognized as one of the most established names in dermatology and consumer product clinical testing. With operations across the U.S. and Canada, Hill Top pioneered industry-standard models for antiperspirant efficacy, HRIPT (Human Repeat Insult Patch Test), sensitization studies, skin irritation and vasoconstrictor assessments, and sunscreen performance testing. Over decades, it supported Phase I–IV clinical trials across dermatology and personal healthcare, serving leading global consumer brands. Today, HillTop’s legacy is fully integrated into Cliantha’s portfolio—fortifying our ability to deliver scientifically validated data, regulatory-ready submissions, and comprehensive product-to-market support.

In 2014, Cliantha expanded its capabilities through the acquisition of Karmic Labs Pvt. Ltd., a full-service, ICH-GCP compliant Contract Research Organization (CRO). Karmic Labs brought in deep expertise across clinical trial management, clinical data management, biostatistics, medical writing, pharmacovigilance, and strategic consulting for pharmaceutical, biotech, and medical device companies

In 2017, Cliantha acquired Inflamax Research, a Canadian CRO founded in 2008 and recognized for its specialized expertise in early- and late-phase clinical trials in allergy testing , asthma, ocular disease, and tobacco research. Inflamax is known for its patented Environmental Exposure Chamber (EEC) technology—an advanced system enabling precise, real-time simulation of allergen exposure to support targeted allergy and respiratory studies. Its capabilities included fixed-site and ambulatory/mobile EEC setups, allowing controlled allergen challenges across diverse study environments. Today, Inflamax’s technical expertise and infrastructure are fully integrated into Cliantha’s global research portfolio, strengthening our ability to deliver scientifically robust, patient-centric clinical outcomes.

As a learning partner, Cliantha Academy builds and elevates clinical research expertise, enabling our community to make a meaningful difference for patients worldwide.

About us

Evolving, Pivoting, Growing: Our Journey to Becoming the Preferred CRO in the Industry

Our Journey of Excellence

Unified under Cliantha, Delivering Excellence Across Services